These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19358841)

  • 1. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
    Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
    Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collagen-induced arthritis.
    Sun P; Liu Y; Deng X; Yu C; Dai N; Yuan X; Chen L; Yu S; Si W; Wang X; Wu D; Liu S; Pang H
    Phytomedicine; 2013 Aug; 20(11):975-9. PubMed ID: 23746958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myricetin ameliorates the symptoms of collagen-induced arthritis in mice by inhibiting cathepsin K activity.
    Yuan X; Liu Y; Hua X; Deng X; Sun P; Yu C; Chen L; Yu S; Liu S; Pang H
    Immunopharmacol Immunotoxicol; 2015; 37(6):513-9. PubMed ID: 26525510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
    Konda VR; Desai A; Darland G; Bland JS; Tripp ML
    Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
    Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT
    J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
    Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
    Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation.
    Hou WS; Li Z; Gordon RE; Chan K; Klein MJ; Levy R; Keysser M; Keyszer G; Brömme D
    Am J Pathol; 2001 Dec; 159(6):2167-77. PubMed ID: 11733367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
    Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
    Bone; 2011 Dec; 49(6):1351-6. PubMed ID: 21982869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice.
    Funato S; Matsunaga A; Oh K; Miyamoto Y; Yoshimura K; Tanaka J; Suzuki D; Uyama R; Suzuki H; Mishima K; Nakamura M; Namiki O; Baba K; Inagaki K; Kamijo R
    J Negat Results Biomed; 2014 Dec; 13():18. PubMed ID: 25495344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis.
    Hayami T; Zhuo Y; Wesolowski GA; Pickarski M; Duong LT
    Bone; 2012 Jun; 50(6):1250-9. PubMed ID: 22484689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice.
    Shiota N; Kovanen PT; Eklund KK; Shibata N; Shimoura K; Niibayashi T; Shimbori C; Okunishi H
    Br J Pharmacol; 2010 Feb; 159(3):626-35. PubMed ID: 20067475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
    Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
    Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
    Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
    Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cathepsin k inhibitor basicity on in vivo off-target activities.
    Desmarais S; Black WC; Oballa R; Lamontagne S; Riendeau D; Tawa P; Duong LT; Pickarski M; Percival MD
    Mol Pharmacol; 2008 Jan; 73(1):147-56. PubMed ID: 17940194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
    Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
    Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
    Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
    J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
    Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
    J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction.
    Hummel KM; Petrow PK; Franz JK; Müller-Ladner U; Aicher WK; Gay RE; Brömme D; Gay S
    J Rheumatol; 1998 Oct; 25(10):1887-94. PubMed ID: 9779840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.